Support & Resources

Order Support
Ordering Information Quick Order Find a Distributor Contact Customer Service Request Custom Conjugation

Technical Resources
Frequently Asked Questions (FAQs) Tech Tips & Protocols Product Safety Reports Publications & Highlighted Citations Fluorescence Spectra Viewer Molarity Calculator

Technical Support

Product Protocols & SDS Storage, Shelf Life & Shipping Contact Technical Support Request a Certificate of Analysis (CoA)

Product Selection Guides

CF® Dye Selection Tool Cellular Stains Selection Guides Membrane & Cell Surface Stains Comparison Secondary Antibody Product Listings Antibody Finder Brochure Library
+1
Back to Highlighted Citations

Introduction of extracellular matrix inhibits glioma cell proliferation

RELATED PAGES
NucView® Caspase-3 Substrates Biotium's fluorogenic substrates for following caspase-3 activity in whole cells and in real-time
Cell Viability & Apoptosis Wide variety of assay kits for apoptosis, necrosis, and cell proliferation
NucView® Caspase 3 Substrates
SHARE ARTICLE

Share this article with a colleague.

Copy Link
Send Email

Evidence shows that manipulation of the extracellular matrix (ECM), a major component of a tumor’s microenvironment, can have suppressive effects on various cancers, including breast, urinary bladder, and prostate cancers. According to the tissue organization field theory, manipulating tumor microenvironments can impact the survival of cancer cells. However, this theory has not yet been tested in glioblastoma multiforme, an aggressive cancer with a poor prognosis for patients.

In a recent publication in Oncotarget, M. H. Murdock et al. investigated the in vitro and in vivo effects of a saline-soluble fraction of non-neoplastic ECM harvested from porcine urinary bladder (ECM-SF) on glioma cells. ECM-SF, which is easily acquired and FDA-approved for clinical applications, was shown to induce apoptosis in glioma cells in vitro. Apoptosis in glioma cells was confirmed using NucView® 488, which showed increasing amounts of nuclear fluorescence over 12 hours of ECM-SF treatment in primary glioma cells (designated 0319 and 1119 in the figure below) compared to non-neoplastic HMC3 CNS cells. Intratumoral injections of ECM-SF into glioma tumors were shown to decrease tumor volume in vivo and correlated with increased median survival from 24.5 to 51 days in rats.

These results support the hypothesis that ECM and resident cells can influence each other through bidirectional crosstalk. This is thought to be a mechanism by which non-neoplastic cells can be influenced by cancer cells to express cancer-like properties. Likewise, cancer cells could be influenced by non-neoplastic environments to become less cancer-like. Further research on the anti-cancer effects of the ECM is needed to determine a possible role for it in cancer therapy.

From Murdock et al.: Figure 2. Caspase activity of glioma cells in ECM-SF spiked media. After 12 hours in media containing 3 mg/mL ECM-SF and 1.5 uM NucView, there is no fluorescence from HMC3 cells (A), some presence of nuclear fluorescence from 1119 cells (B), and a high presence of nuclear fluorescence from 0319 cells (C). Credit: M. H. Murdock, et al. https://dx.doi.org/10.18632%2Foncotarget.28203 reproduced under the Creative Commons license.

Learn more about Biotium’s NucView® Caspase-3 Substrates and kits as well as our other cell viability and apoptosis reagents and cellular stains for multi-color imaging.

Full Citation:

Murdock, M. H., Hussey, G. S., Chang, J. T., Hill, R. C., Nascari, D. G., Rao, A. V., Hansen, K. C., Foley, L. M., Hitchens, T. K., Amankulor, N. M., & Badylak, S. F. (2022). A liquid fraction of extracellular matrix inhibits glioma cell viability in vitro and in vivo. Oncotarget, 13, 426–438. https://doi.org/10.18632/oncotarget.28203